Validating business continuity programmes in the 'new normal'.

Validation activities are essential for organisations to ensure the ongoing efficacy and hence value of their business continuity arrangements. While COVID-19 has impacted the ability to perform normal validation activities in the business continuity life cycle, it has provided the opportunity for a significant live test of recovery strategies, business continuity plans, and response and recovery teams. This paper draws from practical experience with and reviews of approximately 30 Australian companies, and discusses the impacts of COVID-19 on maintenance, exercising and review. It provides suggestions for harnessing and articulating the lessons learned from an unprecedented, global disruptive event, and the adaptation of validation techniques in the new normal to increase both organisational resilience and enhance customer value propositions.

Erratum to: Effects of various doses of lubabegron on calculated ammonia gas emissions, growth performance, and carcass characteristics of beef cattle during the last 56 days of the feeding period.

[This corrects the article DOI: 10.1093/tas/txab137.].

Effects of various doses of lubabegron on calculated ammonia gas emissions, growth performance, and carcass characteristics of beef cattle during the last 56 days of the feeding period.

Lubabegron (LUB; Experior, Elanco, Greenfield, IN, USA) was approved by the U.S. Food and Drug Administration in 2018 and is indicated for the reduction of ammonia (NH3) gas emissions·kg-1 body weight (BW) and hot carcass weight (HCW) when fed to feedlot cattle during the final 14 to 91 d of the finishing period. LUB demonstrates antagonistic behavior at the ß 1 and ß 2 receptor subtypes and agonistic behavior at the ß 3 receptor subtype in cattle and is classified by the Center for Veterinary Medicine as a "beta-adrenergic agonist/antagonist." This report describes a randomized complete block study that evaluated LUB dose (0, 1.5, 3.5, and 5.5 mg·kg-1 dry matter) during the last 56 d of the feeding period on calculated NH3 gas emissions, live weight, carcass weight, and associated ratios in beef feedlot cattle. Carcass characteristics, mobility, and health were also evaluated. All cattle received monensin and tylosin throughout the study. Ammonia gas emissions were calculated using the equation developed by Brown et al. (Brown, M. S., N. A. Cole, S. Gruber, J. Kube, and J. S. Teeter. 2019. Modeling and prediction accuracy of ammonia gas emissions from feedlot cattle. App. Anim. Sci. 35:347-356). The reduction in calculated cumulative NH3 gas emissions with LUB ranged from 1.3% to 11.0% (85 to 708 g/hd). When NH3 gas emissions were expressed on a live weight (unshrunk) and carcass weight basis, calculated NH3 gas emissions decreased by 3.0% to 12.8% and 3.8% to 14.6%, respectively. Daily dry matter intake was 2.3% greater (P trt < 0.05) for steers that received LUB. Average daily gain was 13.7% greater (P trt < 0.05; 1.68 vs. 1.91 kg), while gain efficiency was 10.8% greater (P trt < 0.05; 0.167 vs. 0.185) for steers fed LUB. Animal mobility was scored in the pen approximately 1 wk prior to harvest, when cattle were loaded on trucks scheduled for harvest, and at antemortem inspection during lairage. No treatment differences (P trt ≥ 0.170) were observed at any time for the percent of cattle receiving mobility scores of 1 or 2 (normal or minor stiffness but moving with the normal cattle, respectively). Cattle mobility scored as a 1 or 2 equaled or exceeded 92% at all times. Final BW and HCW increased (P trt < 0.05) 11.6 to 15.7 kg and 11.3 to 17.1 kg, respectively, in cattle receiving LUB compared to cattle receiving monensin plus tylosin alone.

An epidemiological investigation to determine the prevalence and clinical manifestations of slow-moving finished cattle presented to slaughter facilities.

Cattle mobility is routinely measured at commercial slaughter facilities. However, the clinical signs and underlying causes of impaired mobility of cattle presented to slaughter facilities are poorly defined. As such, the objectives of this study were 1) to determine the prevalence of impaired mobility in finished cattle using a 4-point mobility scoring system and 2) to observe clinical signs in order to provide clinical diagnoses for this subset of affected cattle. Finished beef cattle (n = 65,600) were observed by a veterinarian during the morning shift from six commercial abattoirs dispersed across the United States; the veterinarian assigned mobility scores (MS) to all animals using a 1-4 scale from the North American Meat Institute's Mobility Scoring System, with 1 = normal mobility and 4 = extremely limited mobility. Prevalence of MS 1, 2, 3, and 4 was 97.02%, 2.69%, 0.27%, and 0.01%, respectively. Animals with an abnormal MS (MS > 1) were then assigned to one of five clinical observation categories: 1) lameness, 2) poor conformation, 3) laminitis, 4) Fatigued Cattle Syndrome (FCS), and 5) general stiffness. Of all cattle observed, 0.23% were categorized as lame, 0.20% as having poor conformation, 0.72% as displaying signs of laminitis, 0.14% as FCS, and 1.68% as showing general stiffness. The prevalence of lameness and general stiffness was greater in steers than heifers, whereas the prevalence of laminitis was the opposite (P < 0.05). FCS prevalence was higher in dairy cattle than in beef cattle (0.31% vs. 0.22%, respectively; P ≤ 0.05). These data indicate the prevalence of cattle displaying abnormal mobility at slaughter is low and causes of abnormal mobility are multifactorial.